By Rica Bhattacharyya
India’s pharma and healthcare sector saw 57 deals worth $1.30 billion in the quarter ending June. This reflects a drop compared to the previous quarter. Pharma and biotech led in value, driven by capital raises. Hospital platforms saw consolidation and regional expansion. HealthTech and Diagnostics segments attracted investor interest. Public market activity remained subdued with no IPOs recorded.